Open an account

electroCore

ECOR · NASDAQ

$7.49−$0.14 (−1.83%)TodayMarket closed ·
Prev close $7.63

About ECOR

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 83 full-time employees. The company went IPO on 2018-06-22. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.

Employees
83
Headquarters
Rockaway, New Jersey
Listed
Jun 22, 2018
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
electrocore.com

ECOR key statistics

Market cap
67.53M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
84.74K
Volume
55.22K
Open price
$7.52
High today
$8.00
Low today
$7.40
52 Week high
$12.70
52 Week low
$4.41

electroCore (ECOR) at a glance

electroCore (ECOR) last traded at $7.49, with a market cap of 67.53M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.40 and $8.00. The current price is 1.2% above the day's low and 6.4% below its high.

Volume so far is 55.22K shares, below the average of 84.74K shares a day.

Over the past year electroCore has ranged from $4.41 to $12.70, and now sits 37% of the way up that range.

electroCore met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.33 per share against an estimate of -$0.4308.

The average analyst price target is $19.55, 161.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $19.55
Low
$12.12
Now
$7.49
High
$27.30

ECOR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 15.7% on average.

  1. Q3 FY24: reported -$0.31 per share against an estimate of -$0.3417
  2. Q4 FY24: reported -$0.40 per share against an estimate of -$0.3131
  3. Q1 FY25: reported -$0.47 per share against an estimate of -$0.4757
  4. Q2 FY25: reported -$0.44 per share against an estimate of -$0.3128
  5. Q3 FY25: reported -$0.40 per share against an estimate of -$0.4046
  6. Q4 FY25: reported -$0.34 per share against an estimate of -$0.4154
  7. Q1 FY26: reported -$0.37 per share against an estimate of -$0.6246
  8. Q2 FY26: reported -$0.33 per share against an estimate of -$0.4308

ECOR news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseACCESSWIRE

    Ecora Resources PLC Announces Half year results

Similar companies

Companies in the same industry as electroCore

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.